{"name":"Aileron Therapeutics, Inc.","slug":"aileron-therapeutics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":11029000,"netIncome":-49871000,"cash":3215000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2017"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"ALRN-6924 in combination with cytarabine","genericName":"ALRN-6924 in combination with cytarabine","slug":"alrn-6924-in-combination-with-cytarabine","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"ALRN-6924 in combination with cytarabine","genericName":"ALRN-6924 in combination with cytarabine","slug":"alrn-6924-in-combination-with-cytarabine","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"date":"2026-03-26","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxPLVBJeFZJZml5ekJDN2c5WVZScTlYV0hlelcwdzQxMlhVMkoxcTd1aVRYUzA0cXpRbHptXzd3QVl1UWxDYUVNVmZtR203azJwOF9wNE43YlFyc3F2RjhDZ1l2dlJzZzJrWWRCM0M1a1pYSTdxUTkwdDJfcUNFRERYS1FBMzZRNlEtZGZLU3ozTk1PV25jSGNJ?oc=5","date":"2026-03-11","type":"pipeline","source":"openPR.com","summary":"Peripheral T-Cell Lymphoma Market Outlook 2034: US Market - openPR.com","headline":"Peripheral T-Cell Lymphoma Market Outlook 2034: US Market","sentiment":"neutral"},{"date":"2026-03-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-02-19","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-01-16","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-12-11","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-11-14","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2025-11-03","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-10-24","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-10-09","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-09-22","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-09-09","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE1jd1F0U3Z1YkVtamhpMmNhdVJRcDhQZ0o5VXNxeGRtT01lRXFfMlowdFZITmtqa19fak5laDU2ZC04eEs3cFZrY0oxOG9YVXZDcmRJ?oc=5","date":"2025-04-24","type":"pipeline","source":"Stock Titan","summary":"ALRN Stock Price, News & Analysis - Stock Titan","headline":"ALRN Stock Price, News & Analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxPd3Y0UmJqSGltRUxfTmswX0h3NzhiYV9iZERES3FmRVY2SllnbzZhc3gyOVBRR3dZRUpMZFQwRnIwUU5WNEN5cUZKazF0alpJY1RBaVpNdmxneWZ3a2szR0Ixb3pfb1JzZC1idkJENnZBdzFiQ2R5b01hUVlOVEY2d3hxS3BiNjAzNjFQbFhB?oc=5","date":"2025-01-16","type":"pipeline","source":"Fierce Pharma","summary":"Aileron straps in for 2025 with a new name: Rein Therapeutics - Fierce Pharma","headline":"Aileron straps in for 2025 with a new name: Rein Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxQdUkwZDZnVk5aTlpVQVQ1VFpWZEpSOVFaaU1mN3BPcFlIZUhIMVRDaXZ5M01xb2ktMHp5akVWM1gyVlZIUkQtbk1JQlVWaTVvRmZVZVg2WHBFU3FuSWZReFFNR1VvS21XelZNQ0llS25qTHRSWlFsM3FrSDFDMFM2ODFOWXdSQm9ERTQtc3FjSzRHTi0wQS1kSUdjd1hPdWZoaXlhX2xKYTlZSjJIV1Vnci1CbzZpR0RhQkE?oc=5","date":"2025-01-10","type":"pipeline","source":"PR Newswire","summary":"Aileron Therapeutics Announces Rebranding to Rein Therapeutics - PR Newswire","headline":"Aileron Therapeutics Announces Rebranding to Rein Therapeutics","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":0,"revenuePeriod":"2017-12-31","revenueHistory":[{"value":0,"period":"2017-12-31"},{"value":0,"period":"2016-12-31"},{"value":0,"period":"2015-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":11029000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-49871000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":3215000,"cashHistory":[],"totalAssets":24158000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}